Mainstream

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position

Post ContentroivRead More

You might also be interested in reading Bitcoin retail, ETF outflows mount to $494M, analysts eye market bottom.

February 10, 2025
In Mainstream